HIGH DOSE CARBOPLATIN AND PACLITAXEL WITH G-CSF IN NON-SMALL CELL LUNG CANCER

高剂量卡铂和紫杉醇联合 G-CSF 治疗非小细胞肺癌

• 批准号: 6113933
• 负责人: Thomas C. Shea
• 金额: $ 1.58万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6113933
• 关键词: carboplatin; clinical research; colony stimulating factor; combination chemotherapy; drug administration rate /duration; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; nonsmall cell lung cancer; paclitaxel

The primary objective is to assess the response rate to two-21-day cycles of high dose chemotherapy with carboplatin and paclitaxel supported G-CSF and peripheral blood progenitor cells in patients with Stage III non-small cell lung cancer. The secondary objectives are: a) to evaluate the hematologic and non-hematologic toxicity of this induction treatment, and b) to evaluate the toxicity and feasibility of administering 6600 cGvXRT to nonsurgical patients who have been treated with two cycles of high-dose carboplatin and paclitaxel.

主要目的是评估2 -21天的反应率 卡铂和紫杉醇大剂量化疗周期 支持的G-CSF和外周血祖细胞， 非小细胞肺癌的治疗 次要目的是： a）评价该药物的血液学和非血液学毒性， 诱导治疗，和B）评价毒性和可行性 对非手术患者给予6600 cGvXRT， 接受了两个周期的大剂量卡铂和紫杉醇治疗